Frontiers in allergy最新文献

It has been estimated that Nonsteroidal Anti-inflammatory drug (NSAID) Exacerbated Respiratory Disease (N-ERD) previously named as Aspirin Exacerbated Respiratory Disease (A-ERD) affects around 1.4 million persons in the United States. Its prevalence in asthmatic patients has widely been underestimated, as a considerable number of patients would need an aspirin provocation test to confirm the diagnosis. N-ERD physiopathology is somehow complex, but basically involves an imbalance in the arachidonic acid metabolite pathway. The syndrome is characterized by the presence of asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) and NSAID and aspirin intolerance. Despite maximal and comprehensive medical treatment, the disease tends to be severe, with difficult to treat asthma and highly aggressive and recurrent ethmoidal polyposis. Recently, monoclonal antibodies aimed at reducing type 2 inflammation have demonstrated very promising results on disease control. The goal of this review is to provide the most recent published advances and evidence on physiopathology, diagnostic protocols and therapeutic strategies of N-ERD.

Background: Pollen is the most common outdoor allergen that causes allergic rhinitis and asthma, which seriously affects patient quality of life and extensive cross-reactivity occurs between pollen allergens.

Methods: The study enrolled 84 patients with respiratory allergies and at least one pollen allergy who visited the clinic. Specific-IgE was detected via immunoblotting in the sera of patients with positive respiratory allergies to pollen. IgE of the components and cross-reactive carbohydrate determinants (CCD) were evaluated using a fluorescence-encoded microsphere assay.

Results: Our results suggest that Artemisia absinthium, Artemisia vulgaris, Humulus scandens, Amaranthus, Parietaria micrantha allergies are most common in the northern region, and that weed pollen remains the major pollen allergen in the northern region. Among the different age groups, the positive rate of Platanus pollen allergens was significantly higher in patients ≤18 years of age than in those aged >18 years (55.56% vs. 9.17%, χ² = 0.55, p < 0.027). Patients with allergic rhinitis and asthma had an increased positive rate for Betula pollen allergen (20.00% vs. 37.93 χ² = 7.87, p = 0.005) and Platanus pollen allergen (27.27% vs. 51.72%, χ² = 11.05, p = 0.0008) than those with allergic rhinitis alone, although the allergen positivity rate did not significantly differ between sexes. In addition, the positivity of sIgE of allergen components did not reveal a correlation with clinical symptoms and anti-CCD IgE positivity was 1.19% (1/84) among all patients.

Conclusion: The study found the distribution characteristics of common pollen allergens in Beijing among patients of different ages and genders and with different allergic diseases, as well as the relationship between pollen allergen components and symptoms. The positivity rate of CCD for respiratory allergic diseases in Beijing was not high as well.

The Acari Hypothesis posits that acarians, i.e., mites and ticks, are causative agents of IgE-mediated conditions. This report further develops The Hypothesis, providing rationale for the childhood predilection of allergy. In short, Malassezia, a fungus native to human skin and utterly dependent on sebaceous lipids, prevents allergy by deterring acarians. Because sebum output is limited before puberty, children are more prone to allergy than are adults. Competition for sebaceous lipids by Staphylococcus aureus influences not only Malassezia number-and, consequently, allergic predisposition-but also lipid homeostasis. The latter, in turn, contributes to dyslipidemia and associated conditions, e.g., the metabolic syndrome.

Chronic spontaneous urticaria (CSU) is defined as the occurrence of hives, angioedema, or both, lasting for more than 6 weeks. The treatment is based on the use of antihistamines, omalizumab, and/or cyclosporine following a stepwise algorithm recommended by international guidelines with a high level of evidence. Nevertheless, management can be challenging as some patients do not respond to the suggested drugs or have difficulties accessing them for various reasons. In such cases, phototherapy has been reported as a potential treatment option. The evidence on the effectiveness of phototherapy is limited. Most studies have methodological limitations and involve small numbers of patients. A systematic review and meta-analysis of four studies in 2020 concluded that, despite the limited number of randomized controlled trials and the low level of evidence, considering overall efficacy, risk/benefit balance, and costs, narrow band ultraviolet B therapy (NB-UVB) may be a useful adjunct therapy for CSU. Other studies have suggested that the effectiveness of combined antihistamine and phototherapy appears to be more effective than antihistamine alone, although this is based on very low-quality evidence. Additionally, the risk of recurrence was lower with the combination therapy. The objective of this review was to evaluate the role of phototherapy in the treatment of CSU. While randomized studies with a larger number of participants providing a high level of evidence are still needed, we consider phototherapy to be a valuable tool in specific clinical contexts, such as a bridge to the initiation of other medications or until spontaneous remission of the condition occurs.

Purpose: In Palestine, few studies investigated the prevalence of allergies and the factors associated with their occurrence. An online survey was conducted on health complex University students in Jerusalem to determine the prevalence of allergy rhinitis (AR) and its relationship with indoor environmental exposures.

Methods: This study employed a modified online Google form of the Global Asthma Network's Adult Questionnaire. The data were reported as frequency and percentage. The chi-square test of independence was performed to investigate the association between AR diagnosis and other factors. Multivariable models were used to identify the independent risk factors for AR after adjusting for potential confounders.

Results: Data was collected from a total of 819 participants. The mean age of the participants was 20 ± 2 years and 78.1% (n = 640) were females. The AR diagnostic rate was 10.3%. In addition, having asthma and eczema were found to be substantially associated with AR. Additionally, a family history of AR and other allergens were major predictors of AR. The findings revealed that utilizing animal dung for heating increased the likelihood of AR fourfold (AOR = 4.870, p-value = 0.004), whereas e-cigarette vaping increased the possibility of AR by 2.5 times. However, using natural gas for cooking was not significantly associated with AR, and participant age was only slightly associated with AR diagnosis.

Conclusions: Our study found that the AR prevalence rate is low when compared to the same population in other countries. Genetics, biomass fuel consumption, and e-smoking are all significant risk factors for AR in Palestine. An awareness campaign must be developed to educate university students and the general public about the risks of smoking, indoor air pollution, respiratory disorders, and AR. Longitudinal research is required to discover whether these associations are only transient.

A 47-year-old woman presents to our clinic with a chief complaint of rhinorrhea; she had chronic hypertension managed with four antihypertensive drugs, including an ACE inhibitor. While dry cough is a well-known side effect associated with ACE inhibitors, this case highlights a common chief complaint yet less recognized side effect of ACE inhibitors and further emphasizes the idea that overall, angiotensin receptor blockers may be a better drug of choice in hypertension due to their favorable side effect profile.

Introduction: Eosinophilic esophagitis (EoE) is a chronic immune-mediated disorder characterized by eosinophilic infiltration of the esophageal mucosa.

Methods: This study aimed to provide insights into the clinical characteristics, diagnostic evaluation, treatment modalities, and outcomes of EoE in a pediatric population through a retrospective analysis of 79 patients followed in a single tertiary referral center between 2014 and 2020.

Results: As expected, a higher male prevalence was observed. Median age at diagnosis was 8.9 years, aligning with the typical presentation in childhood, emphasizing the need for early recognition. Clinical presentation varied, with vomiting, dysphagia, and abdominal pain being the most frequently reported symptoms. IgE-sensitization, food allergy and atopy were highly prevalent, with cow's milk, wheat, egg, soy, and peanuts being the most common allergens. Endoscopy results mostly revealed macroscopic abnormalities with linear furrows and microabscesses/white plaques being the most common features although a significant proportion of initial endoscopies (14/79) showed no macroscopic abnormalities, highlighting the importance of esophageal biopsies. Proton pump inhibitors (PPIs) were commonly used as a first-line treatment, with most patients receiving PPI therapy. Other treatment modalities, such as oral budesonide and exclusion diets either single or in combination, were also used. Remission was achieved in 69/79 or 87% patients, with different treatment regimens contributing to successful outcomes but subject to relapse upon time.

Discussion: This study provides valuable insights into the clinical characteristics, diagnostic evaluation, treatment modalities, and outcomes of EoE in the pediatric population. It underscores the importance of early recognition, accurate diagnosis, and regular follow-up to effectively manage this chronic immune-mediated disorder but also demonstrates its complexity in real-life clinical setting.

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disorder that affects millions worldwide, presenting challenges in managing symptoms and quality of life. Current treatments include topical corticosteroids (TCS), but novel approaches, such as Janus kinase (JAK) inhibitors, show promise. Baricitinib, a selective JAK1 and JAK2 inhibitor, targets cytokines involved in AD and offers potential benefits beyond traditional therapies.

Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) was performed to evaluate the efficacy and safety of baricitinib in treating moderate-to-severe AD. We followed PRISMA guidelines and assessed data from PubMed, Cochrane Central, ScienceDirect, and ClinicalTrials.gov up to August 2024. The analysis included trials comparing baricitinib to placebo, with or without TCS, evaluating outcomes such as Investigator's Global Assessment (IGA) scores, Eczema Area and Severity Index (EASI) scores, and safety profiles.

Results: Six RCTs involving 2,595 participants met the inclusion criteria. Baricitinib demonstrated significant improvements in IGA scores, EASI scores, Dermatology Life Quality Index (DLQI), and other outcome measures compared to placebo. The efficacy was consistent across different dosages (1 mg, 2 mg, 4 mg) and whether baricitinib was used with or without TCS. Safety analyses revealed a significant increase in treatment-emergent adverse events (TEAEs), particularly with the 2 mg and 4 mg dosages and with TCS.

Conclusion: Baricitinib, both alone and in combination with TCS, significantly improves symptoms and quality of life in patients with moderate-to-severe AD, with efficacy consistent across dosages. The safety profile is overall acceptable, though a significant increase in TEAEs was observed, particularly with higher dosages and when used with TCS. Ongoing monitoring of TEAEs is recommended, and future trials with longer follow-up periods are suggested to better understand long-term outcomes.

Introduction: The clinical significance of elevated baseline serum tryptase (BST) in the absence of mast cell disorders or allergic reactions has long been unclear. Recently, a genetic variation of the TPSAB1 gene, which among others encodes for alpha tryptase, has been reported and named hereditary alpha tryptasemia (HaT). HaT has been linked to various manifestations, including severe allergic reactions. However, clinical studies are limited. In this study, we aimed to determine HaT prevalence and characterize its clinical manifestations in patients at a specialized allergy center.

Methods: From January 2022 to December 2023, patients with elevated BST at least once were screened for HaT at the outpatient clinic. A control group included patients with a history of anaphylaxis undergoing specific Hymenoptera immunotherapy. TPSAB1 copy numbers, BST levels, and clinical parameters were assessed and analyzed.

Results: Of 47 patients with elevated BST (≥11.4 µg/L), 93% showed increased TPSAB1 copy numbers. Individuals diagnosed with HaT displayed a BST range between 12.3 and 28.4 µg/L, with 84.1% associated with TPSAB1 duplication and 15.9% with triplication. HaT predominated in women (86.4%) and was associated with thyroid disease (27.3%). Over half had a history of anaphylaxis (54.5%), which was mainly low-grade.

Discussion: In patients with elevated BST but no mastocytosis, the most likely cause of elevated BST was an increase in the copy number of the TPSAB1 gene. A heightened risk of anaphylaxis should be considered. Further research is needed to explore the predominance of women and the emerging link with thyroid disease.

Background: A disintegrin and metalloproteinase 8 (ADAM8) has been implicated in eosinophilic inflammation; however, its role in chronic rhinosinusitis with nasal polyps (CRSwNP) remains to be elucidated. This study aimed to investigate the predictive significance of ADAM8 levels in nasal secretions for the endotypes and disease control status of CRSwNP.

Methods: A cohort comprising 120 CRSwNP patients and 45 healthy controls (HCs) was assembled, delineating 53 non-eosinophilic CRSwNP (neCRSwNP) and 67 eosinophilic CRSwNP (eCRSwNP) patients. Immunohistochemistry and enzyme-linked immunosorbent assay (ELISA) were utilized to measure ADAM8 levels in nasal mucosal tissues and secretions from all participants. The receiver operating characteristic (ROC) curves and Pearson correlation analysis were employed to assess the predictive capability of ADAM8 levels in predictiving CRSwNP endotypes and disease control status.

Results: ADAM8 levels in nasal secretions were elevated in CRSwNP patients compared to HCs, with a more pronounced increase observed in eCRSwNP patients. Elevated ADAM8 concentrations in nasal secretions were positively correlated with peripheral blood eosinophil counts and percentages, tissue eosinophil counts, serum total IgE, Lund-Mackay scores, and Lund-Kennedy scores. Ultimately, 103 CRSwNP patients completed the follow-up protocol, with 72 classified as the controlled group and 31 as the uncontrolled group. Uncontrolled CRSwNP patients exhibited significantly higher ADAM8 levels in nasal secretions compared to the controlled group. The ROC curves indicated that ADAM8 in nasal secretions exhibits robust discriminatory capacity for eCRSwNP and postoperative disease control status.

Conclusion: ADAM8 in nasal secretions emerges as a potential novel biomarker for the prognostication of CRSwNP endotypes and the postoperative disease control status.